| 摘要 |
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I,;
wherein the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. |
| 主权项 |
1. A compound of Formula I wherein
R1 is hydrogen or methyl, wherein said methyl is optionally substituted with one to three fluoro;R2 is phenyl substituted with one to five R3;R3 at each occurrence is independently selected from the group consisting of halogen, hydroxy, cyano, C1-6alkyl, C1-6alkoxy, C1-6alkoxy-C1-6alkyl, C3-6cycloalkoxy, C3-6cycloalkyl-(CR4aR4b)m—, C3-6cycloalkoxy-(CR4aR4b)m—, C3-6Cycloalkyl-(CR4aR4b)m—O— or (4- to 6-membered heterocycloalkyl)-(CR4aR4b)m—; wherein said C1-6alkyl, C1-6alkoxy or C1-6alkoxy-C1-6alkyl are each optionally substituted with one to three fluoro and wherein said C3-6cycloalkyl, C3-6cycloalkoxy and (4- to 6-membered heterocycloalkyl) moieties are optionally substituted with one to three substituents independently selected from the group consisting of fluoro, methyl, fluoromethyl, difluoromethyl or trifluoromethyl; or two R3, when attached to adjacent carbons on the phenyl and taken together, can be —(CH2)n—O—, —O—(CH2)o—O— or —(CH2)p—;R4a and R4b are independently hydrogen, methyl, fluoromethyl, difluoromethyl, trifluoromethyl or methoxy;m at each occurrence is independently 0, 1 or 2;n is 2 or 3;is 1 or 2; andp is 3 or 4; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. |
